|
WO2007059533A2
|
|
Uses for camki i and hdacs in the treatment of heart conditions
|
|
US2007015777A1
|
|
Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
|
|
EP1796655A2
|
|
Use of modulators of a novel form of muscle selective calcineurin interacting protein (mcip-1-38) as a treatment for cardiovascular diseases
|
|
US2006110390A1
|
|
Inhibition of Ku as a treatment for cardiovascular diseases
|
|
WO2006007213A1
|
|
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
EP1734999A2
|
|
Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
|
|
WO2005092333A1
|
|
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
EP1737448A1
|
|
(s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
EP1715870A1
|
|
Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
|
|
US2005288331A1
|
|
Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
|
|
AU2004285962A1
|
|
1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
|
|
US2003186289A1
|
|
Model cell systems for screening of anti-hypertrophic therapeutics
|
